SEC Form 4 · accession 0001104659-19-009067
Amphastar Pharmaceuticals, Inc. · AMPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jason B. Shandell
Officer — President and General Counsel · Director
Period of report
Feb 14, 2019
Accepted (ET)
Feb 15, 2019 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001297184
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 14, 2019 | M | 7,519 | $15.23 | D | 175,837 | D | |
| Common Stock | Feb 14, 2019 | S | 7,519 | $23.99 | D | 168,318 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $15.23 | Feb 14, 2019 | M | 7,519 | D | — | Oct 3, 2021 | Common Stock | 7,519 | 0 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 30, 2018.
- F2Shares subject to the option are fully vested and immediately exercisable.